Our objective was to determine if there are substantial variations in the methodology and quality of risk-adjusted analyses and therefore, whether development of best practices for risk-adjusted analyses is warranted.
The developers of TRANSIT claim that their model represents best practice for risk assessments of road tunnels.
The methodology developed draws on good practice for risk assessment and risk management and is designed to be flexible enough to be applicable to different types of risk.
These results emphasize that evaluation of VO2peak should be incorporated into routine clinical practice for risk prediction.
For primary breast cancer, the determination of uPA and PAI-1 antigen levels in tumour tissue extracts has already entered clinical practice for risk stratification and individual therapy decisions in patients with lymph node-negative disease [ 16, 38].
In spite of this, the statistical results confirmed that the McM method, collectively, has the best performance which indicates it would be readily utilized in routine clinical practice for risk stratification, prognosis, and cost-effective preventive therapy.
A limitation of the study is the lack of detailed pathology information on the Barrett segment length and grade of dysplasia, as is current practice for risk stratification of patients with BO.
For example, the determination of antigen levels of uPA and PAI-1 in tissue extracts of primary breast cancer has entered clinical practice for risk-adapted, individual therapy decisions in patients with lymph node-negative disease [ 11, 26].
To begin to remedy this, the U.S. Environmental Protection Agency developed the "Framework for Cumulative Risk Assessment" (referred to in this article as "Framework"; U.S. EPA 2003) that sets out general practices for cumulative risk assessment and called attention to critical gaps.
